Skip to main content
. Author manuscript; available in PMC: 2015 Mar 15.
Published in final edited form as: Int J Cancer. 2013 Sep 30;134(6):1300–1310. doi: 10.1002/ijc.28465

Figure 1.

Figure 1

ASPA expression is decreased in glioma tumors. (a) Quantitative real-time PCR revealed decreased ASPA mRNA expression in recurrent grade III oligodendroglioma, anaplastic astrocytoma and GBM. n = 4. Refer to Supplementary Fig. 2 for analysis of REMBRANDT and TCGA datasets. (b) Western blot (25 μg crude protein homogenate, normalized to actin) densitometric analysis revealed that ASPA expression was decreased in grade II (OII) and grade III (OIII) oligodendroglioma, anaplastic astrocytoma (AA) and glioblastoma (GBM) tumors, but similar to ASPA mRNA, ASPA protein was most significantly decreased in recurrent grade III (ReO) oligodendroglioma relative to normal (N) brain (pathologically normal tissue from patients undergoing surgery for epilepsy). n = 6 normal, 10 GBM, and 4 all others, with 2 representative protein samples shown. (c) Dual-label immunohistochemistry using normal human cerebral cortex (i.e., post-mortem brain) revealed that ASPA was more abundantly expressed in CNPase-positive oligodendrocytes within the corpus callosum (WM) than the overlying isocortex. ASPA expression was also detected within the cortical grey matter (GM, arrowheads) by GFAP-positive astrocytes. Immunohistochemistry using two independent tissue samples confirmed the western blot results that GBM and grade III (GIII) oligodendroglioma tumors possess significantly fewer ASPA immunoreactive cells. Scale bar = 100 μm (left panel), 50 μm (right panel). *p < 0.05, #p ≤ 0.001, ##p ≤ 0.0001.